InterMune said to be working with Evercore on strategic options

It sounds like this InterMune situation is heating up.

Good sources tell me InterMune - a US-based bio-pharmaceutical company that specialises in making a drug to treat idiopathic pulmonary fibrosis - has begun working with bankers from Evercore alongside long-standing financial adviser Goldman Sachs to look at 'strategic options' for the business.

It is believed the appointment of Evercore may lead to a formal auction of InterMune...


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Tuesday, 12 August 2014, 4:15 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation